Studi clinici aperti all’arruolamento


Titolo: 20200469 – “A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer

 

Questo studio indaga, in associazione al trattamento standard chemioimmunoterapico (carboplatino-etoposide-atezolizumab/durvalumab), il ruolo dell’anticorpo bispecifico tarlatamab, diretto contro DLL3 sulle cellule tumorali e CD3 sui linfociti T

 

Principal Investigator: Prof. Pierfrancesco Tassone

 

Per informazioni sull’arruolamento contattare: Dott.ssa Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Titolo: MILES-5: A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC

 

Questo studio valuta se, nei pazienti dai 70 anni in su, sia più efficace la chemioterapia seguita da immunoterapia (durvalumab) a progressione o, viceversa, l’immunoterapia (durvalumab, da solo o in associazione a tremelimumab) seguita da chemioterapia a progressione.

 

Principal Investigator: Prof. Pierfrancesco Tassone

 

Per informazioni sull’arruolamento contattare: Dott.ssa Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Titolo: DeLLphi-304 – Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

 

Studio di fase 3 che va a indagare il beneficio in sopravvivenza globale di tarlatamab rispetto allo standard di cura del carcinoma polmonare a piccole cellule recidivato dopo trattamento a base di platino.

 

Per informazioni sull’arruolamento contattare: Dott.ssa Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Titolo: innovaTV207 – “Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors”

 

In questo studio si indagano l’efficacia e la tollerabilità di tisotumab vedotin, anticorpo farmaco-coniugato diretto contro il fattore tissutale, da solo o in associazione ad altri farmaci, nelle seguenti neoplasie: colon-retto, polmonare non a piccole cellule, pancreas esocrino, testa-collo.

 

Principal Investigator: Prof. Pierfrancesco Tassone

 

Per informazioni sull’arruolamento contattare: Dott.ssa Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Titolo: CA043-001 – An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

 

Studio di fase 1/2 first-in-human che indaga il ruolo di BMS-986288 (una forma modificata di ipilimumab), da solo o in associazione a nivolumab, in vari tumori.

 

Principal Investigator: Prof. Pierfrancesco Tassone

ARRUOLAMENTO ATTUALMENTE NON ATTIVO

 


Studi clinici chiusi all’arruolamento

Titolo: EVOKE-01 – “Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Immunotherapy”


Titolo: CA209-73L – “A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)”

Principal Investigator: Prof. Pierfrancesco Tassone


Titolo: ROME – “The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: CANOPY-2 – “A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: D4194R00005 – “First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: MK7902-007 – “A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)”

Principal Investigator: Prof. Pierfrancesco Tassone


Titolo: MS200647_0037 – “An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer”

Principal Investigator: Prof. Pierfrancesco Tassone


Titolo: BE-PACIFIC – “Italian oBsErvational study on Patient mAnagement strategies in real-world Clinical practIce For patIents with loCally advanced (stage III) NSCLC”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: MO39171 – “A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL)”

Principal Investigator: Prof. Pierfrancesco Tassone


Titolo: OSIRIS – “(OSImertinib Rechallenge TKI in Subsequent line of therapy) A Phase II, Noncomparative, Open label. Multicentre, Study of AZD9291, in Patients with Locally Advanced or Metastatic EGFR mutated, “T760M undetectable or unknown” Non Small Cell Lung Cancer (Stage IIIB-IV) after No immediate Prior EGFR TKI”

Principal Investigator: Prof. Pierfrancesco Tassone


Titolo: CINC280A2201 – “A Phase II, Multicenter Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC)”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: PIvOTAL – “Global treatment Patterns, resource utilization and bIOmarker Testing of Advanced non-small cell Lung cancer”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo:  Vx-001-201 – “Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: Be-Team – “Italian observational study on second-line treatment approaches for EGFR mutated, progressing NSCLC patients in real world clinical practice”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: BEVERLY – “A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: INSIGHT – “A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined With Gefitinib Versus Chemotherapy as Second-Line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-TKI Therapy (EMR 200095-006)”

Principal Investigator: Prof. Pierfrancesco Tassone


Titolo: PROFILE 1014 – “Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo:  CLDK378A2301 – “A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: TORCH – “An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: MO19390 – “Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: STAD-1 – “Multicenter Randomized Phase III Study Comparing Fixed Doses Versus Toxicity Adjusted Dosing of Cisplatin and Etoposide for Patients With Small Cell Lung Cancer”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: MILES-3 – “Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer”

Principal Investigator: Prof. Pierosandro Tagliaferri


Titolo: MILES-4 – “A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC”

Principal Investigator: Prof. Pierosandro Tagliaferri